Description:THZ1, with the CAS number 1604810-83-4, is a small molecule that has garnered attention in the field of medicinal chemistry, particularly for its role as a selective inhibitor of the enzyme CDK7 (cyclin-dependent kinase 7). This compound is characterized by its ability to modulate transcriptional regulation and has potential implications in cancer therapy due to its influence on cell cycle progression and transcriptional control. THZ1 exhibits a unique structure that allows it to effectively bind to the ATP-binding site of CDK7, thereby inhibiting its activity. This inhibition can lead to a decrease in the phosphorylation of RNA polymerase II, ultimately affecting gene expression. Additionally, THZ1 has been studied for its selectivity and potency, making it a valuable tool in research aimed at understanding the role of CDK7 in various biological processes and diseases. Its development represents a significant advancement in targeted therapies, particularly in the context of oncology.
We use cookies to enhance your visit. We do not include advertising.
Please see our Cookies Policy for more details or adjust your preferences in "Settings".
This is the advanced settings system for our own and third-party cookies. Here you can modify parameters that will directly affect your browsing experience on this website. If you wish you may check the list of Cookie types.
Please note that disabling cookies can cause failures in the normal operation of the web.
![Benzamide, N-[3-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]phenyl]-4-[[(2E)-4-(dimethylamino…](https://static.cymitquimica.com/products/IN/thumb/DA001RXR.jpg)
